FGFR1 amplification in squamous NSCLC (~15-20%). Multiple FGFR-TKI trials (lucitanib, AZD...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR1-AMP-NSCLC-SQUAMOUS |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-FGFR1 |
|---|---|
| Variant | amplification (squamous histology, GCN ≥6 / FGFR1/CEN8 ≥2) |
| Disease | DIS-NSCLC |
| ESCAT tier | IIIA |
| Recommended combinations | clinical trial (FGFR-TKI basket; novel agents) |
| Contraindicated monotherapy | erdafitinib (not approved for FGFR1-amp NSCLC; label restricted to FGFR2/3 urothelial) |
| Evidence summary | FGFR1 amplification in squamous NSCLC (~15-20%). Multiple FGFR-TKI trials (lucitanib, AZD4547, BGJ398, erdafitinib) showed modest activity (ORR 5-15%) — FGFR1-amp does not predict robust response. Erdafitinib is NOT approved for FGFR1-amp NSCLC (label is FGFR2/3 in urothelial). Standard squamous NSCLC therapy applies; FGFR1-amp is trial-only actionability. |
Notes
ESCAT IIIA. OncoKB Level 3B. Amplification thresholds vary; no validated companion diagnostic. Standard 1L squamous NSCLC remains pembrolizumab-based combinations.
Used By
No reverse references found in the YAML corpus.